AIGEN Sciences is an AI-driven drug discovery platform that develops small-molecule synthetic drugs targeting intractable diseases with high unmet medical needs. Founded in April 2021 and based in Seoul, the company provides drug research and development services using a proprietary AI platform. Its pipeline includes multiple lead substance optimizations and preclinical candidates. AIGEN aims to advance state-of-the-art AI drug discovery technologies and to transform high-cost, low-efficiency drug discovery into faster, more efficient processes. The company will use the funding to enhance its drug development capabilities and accelerate growth.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2024